Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma

Inclusion Criteria: * Aged 18 years and older. * Confirmed diagnosis of GBM. * Radiographically or histologically proven progression or recurrence of disease at any time after standard of care therapy (radiation, temozolomide, with or without a tumor treatment field device). * Tumor debulking or biopsies may be performed to clinical trial enrollment if indicated and feasible. Exclusion Criteria: * Bevacizumab or targeted therapy within 45 days of enrollment. * Intercurrent immune system disorder such as hypoimmunity (marrow failure, HIV) or hyperimmunity (autoimmune disease). * Unable to complete a standard upfront course of chemoradiotherapy due to disease progression or intolerance of therapy. * History of Gliadel water, GammaTile or other implanted therapeutic agent. * Concurrent use of tumor treatment field devices (e.g. Optune).